🟢 Harmony Biosciences is trading 11.5% up today on record Q2 results and reaffirmed full-year guidance

Harmony Biosciences is trading 11.5% up at $39.58 after reporting record Q2 2026 results driven by strong demand for WAKIX.

• Revenue for the quarter grew 30% year-over-year to $261.3 million, with diluted EPS reaching $1.28, surpassing analyst estimates.
• Management reaffirmed its full-year 2026 net revenue guidance of $1.0 billion–$1.04 billion, reflecting continued confidence in the drug's blockbuster growth trajectory.